Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication

• Autorzy: Schang L M
• Języki publikacji: EN

Słowa kluczowe

EN

virus replication; cyclin-dependent kinase; virus; non-dividing cell; dividing cell; inhibitor

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2003
• Tom: 08
• Numer: 2A
• Opis fizyczny: p.543-544

Twórcy

autor

Schang L M

• University of Alberta, Heritage Medical Research Building, Room 315, Edmonton, Alta. T6G 2S2, Canada

Bibliografia

• 1. Chao, S.H., Fujinaga, K., Marion, J.E., Taube, R., Sausville, E.A., Senderowicz, A.M., Peterlin, B.M. and Price, D.H. Flavopiridol piridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275 (2000) 28345-28348.
• 2. Schang, L.M., Phillips, J. and Schaffer, P.A. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 72 (1998) 5626-5637.
• 3. Wang, D., De la Fuente, C., Deng, L., Wang, L., Zilberman, I., Eadie, C., Healey, M., Stein, D., Denny, T., Harrison, L.E., Meijer, L. and Kashanchi, F. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75 (2001) 7266-7279.
• 4. Senderowicz, A.M., Headlee, D., Stinson, S.F., Lush, R.M., Kalil, N., Villalba, L., Hill, K., Steinberg, S.M., Figg, W.D., Tompkins, A., Arbuck, S.G. and Sausville, E.A. Phase I trial of continuous infusion flavopiridol piridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 16 (1998) 2986-2999.
• 5. Sausville, E.A., Johnson, J., Alley, M., Zaharevitz, D. and Senderowicz, A.M. Inhibition of CDKs as a therapeutic modality. Ann. New York Acad. Sci. 910 (2000) 207-212.
• 6. Schwartz, G.K., Ilson, D., Saltz, L., O’Reilly, E., Tong, W., Maslak, P., Wemer, J., Perkins, P., Stoltz, M. and Kelsen D. Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol piridol Administered to Patients With Advanced Gastric Carcinoma. J. Clin. Oncol. 19 (2001) 1985-1992.
• 7. Senderowicz, A.M. and Sausville, E.A. Preclinical and clinical development of cyclin-dependent kinase modulators [see comments], J. Nat. Cancer Inst. 92 (2000) 376-387.
• 8. Mancebo, H.S., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y., Peng, J., Blau, C., Hazuda, D., Price, D. and Flores, O. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11 (1997) 2633-2644.
• 9. Schang, L.M., Knockaert, M., Shaheen, F., Meijer, L., Malim, M., Gray, N., Bantly, A. and Schaffer, P.A. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild type and drug-resistant strains of HSV and HIV-1 by targeting cellular, not viral proteins. J. Virol. 76 (2002) 7874-7882.
• 10. Nelson, P.J., D’Agati, V.D., Gries, J.-M., Suarez, J.-R. and Gelman, I.H. Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin- dependent kinase inhibitor, flavopiridol piridol. J. Antimicrob. Chemoth. (2003) in press.